Resolved versus Active Chronic Graft-versus-Host Disease: Impact on Post-Transplantation Quality of Life

Saiko Kurosawa, Takuhiro Yamaguchi, Kumi Oshima, Atsumi Yanagisawa, Takahiro Fukuda, Heiwa Kanamori, Takehiko Mori, Satoshi Takahashi, Tadakazu Kondo, Akio Kohno, Koichi Miyamura, Yukari Umemoto, Takanori Teshima, Shuichi Taniguchi, Takuya Yamashita, Yoshihiro Inamoto, Yoshinobu Kanda, Shinichiro Okamoto, Yoshiko Atsuta

Research output: Contribution to journalArticle

Abstract

The aim of this study was to determine whether impaired quality of life (QOL) persisted among patients who experienced resolved chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (allo-HCT). Eligible participants were patients who were relapse-free for 3 years after allo-HCT who were age ≥16 years at the time of transplantation and age ≥20 years without relapse at the time of the survey. The Medical Outcomes Study's 36-Item Short-Form Survey (SF-36), the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), and a visual analog scale (VAS) were administered to assess QOL. Physicians evaluated the current status of chronic GVHD at survey using National Institutes of Health (NIH) criteria, and pretransplantation characteristics and history of GVHD were extracted from the national transplant registry database. Patients without currently active GVHD but with a history of chronic GVHD were categorized as having “resolved GVHD.” Of 1250 patients informed of the study, 1216 provided consent and 1130 were included in the final analysis. A total of 745 patients (66%) had currently active chronic GVHD, 149 (13%) had resolved chronic GVHD, and 236 (21%) never had chronic GVHD after allo-HCT. Multivariable analyses showed that compared with patients with resolved or no chronic GVHD, those with active chronic GVHD reported significantly poorer QOL. The QOL scores were similar in patients with resolved chronic GVHD and those without chronic GVHD. Greater between-group differences were observed in SF-36 Physical component and VAS scores in patients age ≥50 years, but the differences were not statistically significant. Our data indicate that only currently active chronic GVHD has a significant impact on physical, mental, and social QOL in allo-HCT survivors, whereas previous chronic GVHD does not impair QOL if it has been resolved.

Original languageEnglish
JournalBiology of Blood and Marrow Transplantation
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Graft vs Host Disease
Transplantation
Quality of Life
Cell Transplantation
Visual Analog Scale
Transplants
Recurrence
Bone Neoplasms
National Institutes of Health (U.S.)
Survivors
Registries

Keywords

  • Allogeneic hematopoietic cell transplantation
  • Chronic graft-versus-host disease
  • Long-term follow-up
  • Quality of life

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Resolved versus Active Chronic Graft-versus-Host Disease : Impact on Post-Transplantation Quality of Life. / Kurosawa, Saiko; Yamaguchi, Takuhiro; Oshima, Kumi; Yanagisawa, Atsumi; Fukuda, Takahiro; Kanamori, Heiwa; Mori, Takehiko; Takahashi, Satoshi; Kondo, Tadakazu; Kohno, Akio; Miyamura, Koichi; Umemoto, Yukari; Teshima, Takanori; Taniguchi, Shuichi; Yamashita, Takuya; Inamoto, Yoshihiro; Kanda, Yoshinobu; Okamoto, Shinichiro; Atsuta, Yoshiko.

In: Biology of Blood and Marrow Transplantation, 01.01.2019.

Research output: Contribution to journalArticle

Kurosawa, S, Yamaguchi, T, Oshima, K, Yanagisawa, A, Fukuda, T, Kanamori, H, Mori, T, Takahashi, S, Kondo, T, Kohno, A, Miyamura, K, Umemoto, Y, Teshima, T, Taniguchi, S, Yamashita, T, Inamoto, Y, Kanda, Y, Okamoto, S & Atsuta, Y 2019, 'Resolved versus Active Chronic Graft-versus-Host Disease: Impact on Post-Transplantation Quality of Life', Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2019.05.016
Kurosawa, Saiko ; Yamaguchi, Takuhiro ; Oshima, Kumi ; Yanagisawa, Atsumi ; Fukuda, Takahiro ; Kanamori, Heiwa ; Mori, Takehiko ; Takahashi, Satoshi ; Kondo, Tadakazu ; Kohno, Akio ; Miyamura, Koichi ; Umemoto, Yukari ; Teshima, Takanori ; Taniguchi, Shuichi ; Yamashita, Takuya ; Inamoto, Yoshihiro ; Kanda, Yoshinobu ; Okamoto, Shinichiro ; Atsuta, Yoshiko. / Resolved versus Active Chronic Graft-versus-Host Disease : Impact on Post-Transplantation Quality of Life. In: Biology of Blood and Marrow Transplantation. 2019.
@article{684d870776b545c4b74294ea0d2bb173,
title = "Resolved versus Active Chronic Graft-versus-Host Disease: Impact on Post-Transplantation Quality of Life",
abstract = "The aim of this study was to determine whether impaired quality of life (QOL) persisted among patients who experienced resolved chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (allo-HCT). Eligible participants were patients who were relapse-free for 3 years after allo-HCT who were age ≥16 years at the time of transplantation and age ≥20 years without relapse at the time of the survey. The Medical Outcomes Study's 36-Item Short-Form Survey (SF-36), the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), and a visual analog scale (VAS) were administered to assess QOL. Physicians evaluated the current status of chronic GVHD at survey using National Institutes of Health (NIH) criteria, and pretransplantation characteristics and history of GVHD were extracted from the national transplant registry database. Patients without currently active GVHD but with a history of chronic GVHD were categorized as having “resolved GVHD.” Of 1250 patients informed of the study, 1216 provided consent and 1130 were included in the final analysis. A total of 745 patients (66{\%}) had currently active chronic GVHD, 149 (13{\%}) had resolved chronic GVHD, and 236 (21{\%}) never had chronic GVHD after allo-HCT. Multivariable analyses showed that compared with patients with resolved or no chronic GVHD, those with active chronic GVHD reported significantly poorer QOL. The QOL scores were similar in patients with resolved chronic GVHD and those without chronic GVHD. Greater between-group differences were observed in SF-36 Physical component and VAS scores in patients age ≥50 years, but the differences were not statistically significant. Our data indicate that only currently active chronic GVHD has a significant impact on physical, mental, and social QOL in allo-HCT survivors, whereas previous chronic GVHD does not impair QOL if it has been resolved.",
keywords = "Allogeneic hematopoietic cell transplantation, Chronic graft-versus-host disease, Long-term follow-up, Quality of life",
author = "Saiko Kurosawa and Takuhiro Yamaguchi and Kumi Oshima and Atsumi Yanagisawa and Takahiro Fukuda and Heiwa Kanamori and Takehiko Mori and Satoshi Takahashi and Tadakazu Kondo and Akio Kohno and Koichi Miyamura and Yukari Umemoto and Takanori Teshima and Shuichi Taniguchi and Takuya Yamashita and Yoshihiro Inamoto and Yoshinobu Kanda and Shinichiro Okamoto and Yoshiko Atsuta",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.bbmt.2019.05.016",
language = "English",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Resolved versus Active Chronic Graft-versus-Host Disease

T2 - Impact on Post-Transplantation Quality of Life

AU - Kurosawa, Saiko

AU - Yamaguchi, Takuhiro

AU - Oshima, Kumi

AU - Yanagisawa, Atsumi

AU - Fukuda, Takahiro

AU - Kanamori, Heiwa

AU - Mori, Takehiko

AU - Takahashi, Satoshi

AU - Kondo, Tadakazu

AU - Kohno, Akio

AU - Miyamura, Koichi

AU - Umemoto, Yukari

AU - Teshima, Takanori

AU - Taniguchi, Shuichi

AU - Yamashita, Takuya

AU - Inamoto, Yoshihiro

AU - Kanda, Yoshinobu

AU - Okamoto, Shinichiro

AU - Atsuta, Yoshiko

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The aim of this study was to determine whether impaired quality of life (QOL) persisted among patients who experienced resolved chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (allo-HCT). Eligible participants were patients who were relapse-free for 3 years after allo-HCT who were age ≥16 years at the time of transplantation and age ≥20 years without relapse at the time of the survey. The Medical Outcomes Study's 36-Item Short-Form Survey (SF-36), the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), and a visual analog scale (VAS) were administered to assess QOL. Physicians evaluated the current status of chronic GVHD at survey using National Institutes of Health (NIH) criteria, and pretransplantation characteristics and history of GVHD were extracted from the national transplant registry database. Patients without currently active GVHD but with a history of chronic GVHD were categorized as having “resolved GVHD.” Of 1250 patients informed of the study, 1216 provided consent and 1130 were included in the final analysis. A total of 745 patients (66%) had currently active chronic GVHD, 149 (13%) had resolved chronic GVHD, and 236 (21%) never had chronic GVHD after allo-HCT. Multivariable analyses showed that compared with patients with resolved or no chronic GVHD, those with active chronic GVHD reported significantly poorer QOL. The QOL scores were similar in patients with resolved chronic GVHD and those without chronic GVHD. Greater between-group differences were observed in SF-36 Physical component and VAS scores in patients age ≥50 years, but the differences were not statistically significant. Our data indicate that only currently active chronic GVHD has a significant impact on physical, mental, and social QOL in allo-HCT survivors, whereas previous chronic GVHD does not impair QOL if it has been resolved.

AB - The aim of this study was to determine whether impaired quality of life (QOL) persisted among patients who experienced resolved chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (allo-HCT). Eligible participants were patients who were relapse-free for 3 years after allo-HCT who were age ≥16 years at the time of transplantation and age ≥20 years without relapse at the time of the survey. The Medical Outcomes Study's 36-Item Short-Form Survey (SF-36), the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), and a visual analog scale (VAS) were administered to assess QOL. Physicians evaluated the current status of chronic GVHD at survey using National Institutes of Health (NIH) criteria, and pretransplantation characteristics and history of GVHD were extracted from the national transplant registry database. Patients without currently active GVHD but with a history of chronic GVHD were categorized as having “resolved GVHD.” Of 1250 patients informed of the study, 1216 provided consent and 1130 were included in the final analysis. A total of 745 patients (66%) had currently active chronic GVHD, 149 (13%) had resolved chronic GVHD, and 236 (21%) never had chronic GVHD after allo-HCT. Multivariable analyses showed that compared with patients with resolved or no chronic GVHD, those with active chronic GVHD reported significantly poorer QOL. The QOL scores were similar in patients with resolved chronic GVHD and those without chronic GVHD. Greater between-group differences were observed in SF-36 Physical component and VAS scores in patients age ≥50 years, but the differences were not statistically significant. Our data indicate that only currently active chronic GVHD has a significant impact on physical, mental, and social QOL in allo-HCT survivors, whereas previous chronic GVHD does not impair QOL if it has been resolved.

KW - Allogeneic hematopoietic cell transplantation

KW - Chronic graft-versus-host disease

KW - Long-term follow-up

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=85067673266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067673266&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2019.05.016

DO - 10.1016/j.bbmt.2019.05.016

M3 - Article

C2 - 31129353

AN - SCOPUS:85067673266

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

ER -